Viridian Therapeutics (VRDN)
19.17
-0.01 (0.05%)
Upcoming Events
Latest Headlines
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: CAIN CHRISTOPHER W.
July 2, 2026 4:16 PM - SEC Filing
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: Ajer Jeffrey Robert
July 2, 2026 4:16 PM - SEC Filing
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: Gheuens Sarah
July 2, 2026 4:16 PM - SEC Filing
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: Moses Jennifer K.
July 2, 2026 4:16 PM - SEC Filing
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: Morris Arlene
July 2, 2026 4:15 PM - SEC Filing
Form 4 Viridian Therapeutics, For: Jul 01 Filed by: Kiselak Tomas
July 2, 2026 4:15 PM - SEC Filing
Viridian Therapeutic (VRDN) PT Raised to $35 at RBC Capital
June 30, 2026 6:48 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 12:25 PM - StreetInsider
William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'
June 29, 2026 12:25 PM - StreetInsider
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
June 29, 2026 9:51 AM - StreetInsider
Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
June 29, 2026 9:50 AM - StreetInsider
Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight
June 29, 2026 9:43 AM - StreetInsider
Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval
June 29, 2026 9:28 AM - StreetInsider
UBS Reiterates Buy Rating on Viridian Therapeutic (VRDN)
June 29, 2026 8:39 AM - StreetInsider
Comcast, Viridian Therapeutics jump premarket; Doximity slips
June 29, 2026 7:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
June 29, 2026 7:09 AM - StreetInsider
Form 8-K Viridian Therapeutics, For: Jun 26
June 29, 2026 6:02 AM - SEC Filing
Viridian Therapeutic (VRDN) Reiterated at Market Outperform by Citizens: Lumvoa Approved
June 29, 2026 4:47 AM - StreetInsider
FDA approves Viridian's Lumvoa for thyroid eye disease
June 26, 2026 6:00 PM - StreetInsider
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026 6:00 PM - BizWire
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Paradigm Biocapital Advisors LP
June 26, 2026 4:05 PM - SEC Filing
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
June 9, 2026 9:01 AM - Globe NewsWire
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
June 5, 2026 10:00 AM - Globe NewsWire
Form 8-K Viridian Therapeutics, For: Jun 02
June 3, 2026 7:00 AM - SEC Filing
Morgan Stanley: China healthcare sector dips 1.3% amid licensing scrutiny
May 29, 2026 12:07 PM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 27
May 28, 2026 4:49 PM - SEC Filing
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 27, 2026 7:00 AM - BizWire
Form 8-K Viridian Therapeutics, For: May 24
May 26, 2026 4:13 PM - SEC Filing
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
May 19, 2026 1:30 PM - Globe NewsWire
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Bellevue Group AG
May 15, 2026 2:38 PM - SEC Filing
Viridian Therapeutic (VRDN) PT Lowered to $26 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Form 4 Viridian Therapeutics, For: May 11 Filed by: Fairmount Healthcare Fund II GP LLC
May 13, 2026 4:31 PM - SEC Filing
Form SCHEDULE 13D/A Viridian Therapeutics, Filed by: Fairmount Funds Management LLC
May 13, 2026 4:31 PM - SEC Filing
Viridian Therapeutic (VRDN) PT Lowered to $39 at Stifel
May 13, 2026 10:12 AM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 06
May 11, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G Viridian Therapeutics, Filed by: Deep Track Capital, LP
May 8, 2026 4:18 PM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 8, 2026 4:07 PM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 8, 2026 4:06 PM - SEC Filing
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 7, 2026 6:09 AM - SEC Filing
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 7, 2026 6:09 AM - SEC Filing
Form 305B2 Viridian Therapeutics,
May 7, 2026 6:08 AM - SEC Filing
Viridian Therapeutics prices $350 million dual offering with notes and stock
May 6, 2026 11:13 PM - StreetInsider
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
May 6, 2026 11:13 PM - BizWire
Viridian Therapeutic (VRDN) PT Raised to $35 at Truist Securities
May 6, 2026 7:12 AM - StreetInsider
Form 424B5 Viridian Therapeutics,
May 6, 2026 6:07 AM - SEC Filing
Form 424B5 Viridian Therapeutics,
May 6, 2026 6:07 AM - SEC Filing
Viridian Therapeutic (VRDN) PT Raised to $34 at RBC Capital
May 6, 2026 4:20 AM - StreetInsider
Form FWP Viridian Therapeutics, Filed by: Viridian Therapeutics, Inc.\DE
May 5, 2026 5:19 PM - SEC Filing
Viridian Therapeutics announces $250 million in proposed public offerings
May 5, 2026 4:05 PM - StreetInsider
Viridian Therapeutics launches $250 million dual public offering
May 5, 2026 4:05 PM - StreetInsider
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
May 5, 2026 4:05 PM - BizWire
Viridian Therapeutic (VRDN) PT Raised to $28 at Jefferies
May 5, 2026 12:24 PM - StreetInsider
Form 8-K Viridian Therapeutics, For: May 05
May 5, 2026 7:57 AM - SEC Filing
Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 99c
May 5, 2026 7:31 AM - StreetInsider
Form 10-Q Viridian Therapeutics, For: Mar 31
May 5, 2026 7:06 AM - SEC Filing
Form 8-K Viridian Therapeutics, For: May 05
May 5, 2026 7:05 AM - SEC Filing
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 5, 2026 7:01 AM - BizWire
Viridian reports positive Phase 3 results for chronic thyroid eye disease drug
May 5, 2026 7:00 AM - StreetInsider
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 5, 2026 7:00 AM - BizWire
Full Article List
